CPT 95810 Denial Appeal Guide: Attended In-Lab Polysomnography

CPT 95810 is a diagnostic sleep study done overnight in a sleep facility, with a technologist present for the whole recording. A medical necessity denial on 95810 often turns on one question from the payer: why did this patient need a lab study instead of a home test?

What CPT 95810 Covers

In plain terms, 95810 is a full diagnostic sleep study in a sleep lab for a patient age 6 or older, with no positive airway pressure titration that night. What separates it from the other sleep codes:

• Sleep stages are scored. Brain waves (EEG), eye movements (EOG) and chin muscle activity (submental EMG) are recorded so the scorer can separate wake, NREM and REM sleep. CGS LCD L36902 names these three as what sleep staging requires.
• Breathing, oxygen, heart rhythm and other channels are recorded alongside. First Coast's Medicare billing article A57496 lists the additional channels Medicare recognizes, among them ECG, airflow, respiratory effort, oximetry, limb movement and body position, and says 95810 includes four or more of them.
• A technologist is in the lab all night. L36902 describes a technologist physically present who supervises the recording and can intervene if needed. A57496 says a study reported as PSG must be directly attended by a qualified technologist, and that a recording under 6 hours is reported with modifier 52.

Which Code Do You Actually Need?

Some 95810 denials are coding problems. Check the service against this table (built from the code list in First Coast article A57496) before you write an appeal:

Three coding errors are worth ruling out first:

• A split-night study is 95811 only. First Coast's article says 95811 alone is billed for a split-night study because it includes 95810.
• A home test is never 95810. Medicare billing articles from CGS (A57049) and Noridian (A57697) require documentation that 95810 was performed in a facility-based sleep laboratory, not in the home or a mobile facility. If the patient took a portable monitor home, correct the code and resubmit.
• The component channels are not billed separately. Medicare does not expect separate charges for EEG, EOG, EMG or the additional parameters on the same study (A57496).

Common Denial Reasons for CPT 95810

Also confirm the facility, technologist and interpreting physician met your MAC's credential requirements on the date of service. If they did not, no appeal letter will fix it.

Medicare: What the Coverage Policies Require

National policy. NCD 240.4.1 covers Type I (attended, in-lab) PSG to aid the diagnosis of obstructive sleep apnea in beneficiaries with clinical signs and symptoms of OSA, when performed attended in a sleep lab facility.

Local policy. Most MACs publish a sleep testing LCD with a billing article, and the details differ. Current sleep study LCDs include CGS L36902, Noridian L36861, WPS L36839, Palmetto GBA L36593, Novitas L35050 and First Coast L33405. Wellpoint Federal has no sleep testing LCD; its policy article A53019 sets credentialing and documentation rules and defers to the NCD for covered indications. The points below come from the LCDs and articles linked here; read your own MAC's current version:

• Order and referral. The patient is referred by the attending physician and the order is kept in the record (CGS L36902), and the ordering physician's NPI goes on the claim (First Coast A57496).
• Facility, technologist and physician credentials. CGS L36902 requires facility accreditation from the AASM, The Joint Commission or ACHC; a credentialed technologist (for example RPSGT, RST, or one of the listed NBRC credentials); and an interpreting physician with sleep medicine certification or active staff membership at a credentialed sleep center.
• Covered indications beyond OSA. CGS L36902 covers testing for narcolepsy (the LCD says a multiple sleep latency test can only be interpreted after a PSG the night before) and for parasomnias with violent or injurious episodes once seizure disorders are ruled out. It does not cover PSG for chronic insomnia or circadian rhythm disorders, and Novitas L35050 excludes screening of people without symptoms.
• Home testing limits. CGS L36902 covers a home test only after a comprehensive sleep evaluation in a patient with a high pretest probability of moderate to severe OSA, not for patients with moderate to severe pulmonary disease, neuromuscular disease or congestive heart failure, and not for any sleep disorder other than OSA. Novitas L35050 says a negative or technically inadequate home test in a high-probability patient should be followed promptly by in-lab PSG.
• Repeat studies. Novitas L35050 accepts a repeat when the first study was technically inadequate, the patient slept too little for a diagnosis, the results were inconclusive or ambiguous, or therapy needed to be started or confirmed. Noridian's article A57697 says more than two PSGs in a year would not be expected without persuasive medical evidence. When a beneficiary who failed the initial 12-week PAP trial needs a repeat facility-based study to re-qualify for a PAP device, Noridian L36861 asks for the KX modifier and a narrative in item 19 of the CMS-1500.

Commercial, Medicare Advantage and Medicaid Plans

These plans write their own sleep testing policies. Pull the plan's current policy and check whether it expects a home test first for uncomplicated adults, which conditions it accepts as reasons for an in-lab study, and whether the in-lab study needs prior authorization. Then answer the denial in the policy's own terms.

When the policy is silent or vague, cite the clinical standard. The American Academy of Sleep Medicine guideline on diagnostic testing for adult OSA (Kapur et al., Journal of Clinical Sleep Medicine, 2017) recommends:

• PSG or a technically adequate home sleep apnea test for uncomplicated adults with signs and symptoms of increased risk of moderate to severe OSA.
• PSG rather than a home test for patients with significant cardiorespiratory disease, possible respiratory muscle weakness from a neuromuscular condition, awake hypoventilation or suspected sleep-related hypoventilation, chronic opioid use, a history of stroke, or severe insomnia.
• PSG when a single home test is negative, inconclusive or technically inadequate.
• No diagnosis of OSA from questionnaires or prediction tools alone, so a screening score supports pretest probability but is not the argument by itself.

For prior authorization: from January 1, 2026, CMS-0057-F requires Medicare Advantage plans and state Medicaid and CHIP programs to decide standard prior authorization requests within 7 calendar days and expedited requests within 72 hours, and to give a specific reason for a denial. The rule does not cover ordinary employer or commercial plans.

Documentation Checklist

Order and evaluation

• ☐ Signed order from the treating clinician, with the ordering NPI on the claim
• ☐ Sleep evaluation note: snoring, witnessed apneas, daytime sleepiness, relevant exam findings, and any screening questionnaire used
• ☐ For non-OSA indications, the documented symptoms (for suspected narcolepsy, how severe the sleepiness is and how it affects the patient)

Why a lab study instead of a home test

• ☐ The comorbidity that rules out home testing, documented in the chart before the study date
• ☐ Or the prior home test report showing a negative, inconclusive or technically inadequate result
• ☐ Or the non-OSA indication that a home test cannot evaluate

The study itself

• ☐ Report showing start time, recording duration, total sleep time, sleep efficiency, time in each sleep stage, respiratory events, oxygenation, cardiac rhythm and behavioral observations (the parameters CGS L36902 lists)
• ☐ At least 6 hours of recording, or modifier 52 on the claim (First Coast A57496)
• ☐ Interpretation signed by the reading physician

Credentials and administration

• ☐ Facility accreditation, technologist credential and interpreting physician credential in effect on the date of service
• ☐ Prior authorization number, if the plan required one
• ☐ For a repeat study, the earlier report and the reason it did not answer the clinical question
• ☐ The denial notice and the 835 with its CARC and RARC codes

Sample Appeal Language

Adapt these to the chart. Every bracketed item must come from the record, and cite an LCD only for a point it actually makes.

When a home test was not appropriate: "[Patient] underwent attended polysomnography (CPT 95810) on [date] for suspected obstructive sleep apnea. A home sleep apnea test was not appropriate because the patient has [condition], documented on [date]. The AASM guideline for diagnostic testing for adult OSA (Kapur et al., 2017) recommends polysomnography rather than home testing for patients with [condition category]. [For Medicare, only if your MAC's LCD lists this condition: LCD (number) does not cover home sleep testing for patients with (condition).] The evaluation note and study report are enclosed."

When a home test already failed: "A home sleep apnea test on [date] was [negative / inconclusive / technically inadequate] despite [documented symptoms]; the report is enclosed. The AASM guideline recommends polysomnography when a single home test gives this result, and the in-lab study on [date] followed that recommendation."

When the indication is not OSA: "The study was ordered to evaluate suspected [narcolepsy / parasomnia with injurious behavior]. [For narcolepsy: The overnight PSG preceded a multiple sleep latency test on (date); the MSLT cannot be interpreted without a PSG the night before.] [For Medicare, if your MAC's LCD says so: LCD (number) covers home sleep testing only for suspected obstructive sleep apnea, so a home test was not an option for this indication.]"

When the study was a repeat: "The first study on [date] was [technically inadequate because (reason) / too short to support a diagnosis / inconclusive]. The repeat study on [date] was needed to reach a diagnosis; both reports are enclosed."

Appeal Routes and Deadlines

Traditional Medicare. Request a redetermination from the MAC within 120 days of receiving the initial determination; receipt is presumed 5 days after the notice date (CMS). If that fails, request reconsideration by a Qualified Independent Contractor within 180 days of receiving the redetermination. Later levels are an ALJ hearing (60 days), the Medicare Appeals Council (60 days) and federal court (60 days); the ALJ and federal court levels have amount-in-controversy thresholds that change every year. A claim denied with MA130 has no appeal rights: correct it and submit a new claim.

Medicare Advantage. The enrollee, or a non-contracted provider with a waiver of liability, requests plan reconsideration within 65 days of the notice (42 CFR 422.582). If the plan upholds the denial, it is forwarded automatically to the Independent Review Entity. Standard pre-service reconsiderations are decided within 30 days, payment reconsiderations within 60 days, expedited within 72 hours. Contracted providers' payment disputes follow their contract.

Commercial and ERISA group health plans. For ACA-compliant plans, the member or an authorized representative (often the provider) has at least 180 days from the adverse benefit determination to file an internal appeal. After a final internal denial, federal external review must be requested within 4 months; state processes vary. Standard external review decisions come within 45 days, expedited within 72 hours, and a decision binds that claim only. Provider appeals under a participation contract follow the contract, and those windows vary, so check the contract and the denial notice for the exact deadline.

Medicaid. Appeal windows vary by state and managed care plan. Check the denial notice and the plan's provider manual.

Getting the Letters Out Faster

EZAppeal sorts the denials on an 835 into next steps for free, and drafts appeal and prior authorization letters in a few minutes, citing the payer's policy when one is on file, for your team to review and send. Every account signs a BAA, and new accounts get 6 free documents.